Monograph Title Sort ascending | Section | Source Publication | Page Number | Errata Post Date | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
---|---|---|---|---|---|---|---|---|
〈643〉 TOTAL ORGANIC CARBON | PROCEDURES | USPNF 2021 ISSUE 1 | Online | 27-Aug-2021 | 1-Sep-2021 | NA | NA | In 1. Bulk Water/1.10 System suitability: Change rE = 100 × [(rC/rL) to: rE = 100 × (rC/rL) |
〈197〉 SPECTROSCOPIC IDENTIFICATION TESTS | INTRODUCTION AND SCOPE | USPNF 2021 ISSUE 1 | Online | 27-Aug-2021 | 1-Sep-2021 | NA | NA | Change (see Mid-Infrared Spectroscopy 〈854〉, Ultraviolet-Visible Spectroscopy 〈857〉, X-Ray Powder Diffraction 〈941〉, Near-Infrared Spectroscopy—Theory and Practice 〈1856〉, and Raman Spectroscopy 〈858〉. to: (see … Read More |
〈1051〉 CLEANING GLASS APPARATUS | CLEANING VALIDATION BEST PRACTICES | USPNF 2021 ISSUE 1 | Online | 27-Aug-2021 | 1-Sep-2021 | NA | NA | In Table 2: Change and verify levels are below Loss on Drying 〈731〉. to: and verify levels are below limit of detection. |
ZONISAMIDE CAPSULES | PERFORMANCE TESTS/Dissolution <711> | USP41–NF36 | 4410 | 27-Apr-2018 | 1-May-2018 | USP42–NF37 | Second Supplement to USP41–NF36 | Line 1 of Apparatus 2: Change 75 rpm, with sinkers (see Dissolution <711>, Figure 2a) to: 75 rpm. Use suitable sinkers, if necessary. |
ZONISAMIDE | IMPURITIES/Organic Impurities | USP42–NF37 | 4675 | 28-Jun-2019 | 1-Jul-2019 | NA | NA | In Analysis: Change CU = concentration of zonisamide related compound A in the Sample solution (mg/mL) to: CU = concentration of zonisamide in the Sample solution (mg/mL) |
ZONISAMIDE | IDENTIFICATION/A. | USP43–NF38 | 4718 | 25-Sep-2020 | 1-Oct-2020 | NA | NA | Change Infrared Absorption 〈197K〉 to: Spectroscopic Identification Tests 〈197〉, Infrared Spectroscopy: 197K |
ZOLMITRIPTAN TABLETS | IMPURITIES/Organic Impurities | Revision Bulletin (Official November 01, 2017) | Online | 26-Oct-2018 | 1-Nov-2018 | USP43–NF38 | Second Supplement to USP41–NF36 | Line 2 of Analysis: Change Sample: Sample solution to: Samples: Standard solution and Sample solution |
ZOLEDRONIC ACID | IMPURITIES/Organic Impurities | USPNF Online | Online | 25-Feb-2022 | 1-Mar-2022 | NA | NA | In Analysis: Change rU = peak response of zoledronic acid from the Sample solution to: rU = peak response of any individual impurity from the Sample solution |
ZIPRASIDONE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP43–NF38 | 4699 | 30-Jul-2021 | 1-Aug-2021 | NA | NA | In USP Ziprasidone Related Compound F RS: Change 2-(2-Amino-5-{2-[4-(benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl}-4-chlorophenyl)acetic acid. C21H23ClN4O2S 430.95 to: Sodium 2-(2-… Read More |
ZIPRASIDONE HYDROCHLORIDE | IMPURITIES/Organic Impurities/Analysis | Second Supplement to USP41–NF36 | 8993 | 25-May-2018 | 1-Jun-2018 | USP42–NF37 | Second Supplement to USP41–NF36 | In the second Calculate statement: Change chloroindolinone and ziprasidone related compound F to: chloroindolinone, ziprasidone related compound F, and any individual unspecified impurity AND In the second variable definition list: Change F… Read More |
ZIPRASIDONE HYDROCHLORIDE | IMPURITIES/Organic Impurities | Second Supplement to USP41–NF36 | 8992 | 27-Jul-2018 | 1-Aug-2018 | USP43–NF38 | Second Supplement to USP41–NF36 | In the second variable definition in Analysis: Change rU = peak response of chloroindolinone or ziprasidone related compound F from the Sample solution to: rU = peak response of chloroindolinone,… Read More |
ZIPRASIDONE HYDROCHLORIDE | IMPURITIES | USPNF Online | Online | 25-Aug-2023 | 1-Sep-2023 | NA | NA | In Organic Impurities/Solution B: Change Acetonitrile, methanol, and Buffer (55:5:40). Adjust with potassium hydroxide TS to a pH of 6.0. to: Acetonitrile, methanol, and Buffer (55:5:40). Adjust with potassium hydroxide solution… Read More |
ZIPRASIDONE HYDROCHLORIDE | IMPURITIES/Limit of Tetrahydrofuran | USP37–NF32 | 5219 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Standard solution: Change 0.05 mg/mL of USP Ziprasidone Hydrochloride RS in dimethyl sulfoxide to: 0.05 mg/mL of tetrahydrofuran in dimethyl sulfoxide |
ZIPRASIDONE CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Test 3/Tier 2 | Revision Bulletin (Official October 01, 2019) | Online | 22-Nov-2019 | 1-Dec-2019 | NA | NA | In Buffer: Change 6.8 g/L g to: 6.8 g/L AND In Standard stock solution 2: Change Standard stock solution to: Standard stock solution 1 |
ZIPRASIDONE CAPSULES | ASSAY | USPNF Online | Online | 25-Aug-2023 | 1-Sep-2023 | NA | NA | In Procedure/Analysis: Change 449.40 to: 449.39 |
ZIPRASIDONE CAPSULES | PERFORMANCE TESTS | USPNF Online | Online | 25-Aug-2023 | 1-Sep-2023 | NA | NA | In Dissolution 〈711〉/Test 1/Tier 1/Phosphate buffer, pH 7.5: Change sodium hydroxide to: sodium hydroxide solution AND In Dissolution 〈711〉/Test 1/Tier 1/Analysis: Change 449.40 to… Read More |
ZIPRASIDONE CAPSULES | IMPURITIES | USPNF Online | Online | 25-Aug-2023 | 1-Sep-2023 | NA | NA | In Organic Impurities/Solution B: Change potassium hydroxide to: potassium hydroxide solution AND In Organic Impurities/Analysis: Change 449.40 to: 449.39 |
ZINC UNDECYLENATE | ASSAY/Procedure | USPNF Online | Online | 18-Nov-2022 | 1-Dec-2022 | NA | NA | In Solution A: Change 0.15 N hydrochloric acid in water prepared as follows. Transfer 150 mL of hydrochloric acid to a 500-mL volumetric flask, dilute with water to volume, and mix well. to: 0.15 N hydrochloric acid in water prepared as follows.… Read More |
ZINC SULFATE TABLETS | Identification/B. Zinc | USP35–NF30 | 5077 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 1 of Sodium hydroxide solution: Change 42 mg/mL of sodium hydroxide to: 420 mg/mL of sodium hydroxide |
ZINC SULFATE | CHEMICAL INFORMATION | USP42–NF37 | 4649 | 27-Sep-2019 | 1-Oct-2019 | NA | NA | Change Zinc sulfate (1:1) monohydrate 179.46 to: Zinc sulfate (1:1) monohydrate 179.45 [7446-19-7]. AND Change 287.56 to: 287.54 |
ZINC GLUCONATE | IMPURITIES/Limit of Cadmium | USP35–NF30 | 5070 | 31-Jan-2013 | 1-Feb-2013 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 22 of Analysis: Change W = weight of Calcium Gluconate taken to prepare Sample solution A (g) to: W = weight of Zinc Gluconate taken to prepare Sample solution A (g) |
ZINC CARBONATE | IMPURITIES/Iron <241> | USP35–NF30 | 5068 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Line 1 of Sample solution: Change
Sample solution: Dissolve 1.0 g in 20 mL of water and 3 mL of hydrochloric acid. to: Test preparation: Dissolve 0.5 g in 20 mL of water and 3 mL of hydrochloric acid. |
Zinc Acetate | REAGENTS AND REFERENCE TABLES/Reagent Specifications | USP43–NF38 | 6219 | 30-Jul-2021 | 1-Aug-2021 | NA | NA | Change [557-34-6]. to: [5970-45-6]. |
ZILEUTON | USP Reference standards <11> | USP43–NF38 | 4679 | 26-Mar-2021 | 1-Apr-2021 | NA | NA | In USP Zileuton Related Compound A RS: Change N-(1-Benzo-[b]thien-2-ylethyl)urea. C11H12N2OS 220.30 to: N-(1-Benzo-[b]thien-2-ylethyl)urea; Also known as 1-[1-(Benzo… Read More |
ZEIN | IDENTIFICATION/C. SDS-Polyacrylamide Gel Electrophoresis | USP35–NF30 | 2019 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Lines 1 and 2 of the Acceptance criteria: Change
Zein has two major bands: the α band is at 21–25 kDa, and the β band is at 17–18 kDa. to: Zein has two major bands for α-zein at 19–26 kDa. |
ZANAMIVIR | ASSAY/Procedure/Chromatographic system | USP37–NF32 | 5197 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Column: Change 5-μm packing L##1 to: 5-μm packing L82 AND Delete footnote 1 |
ZANAMIVIR | IMPURITIES/Organic Impurities/Chromatographic system | USP37–NF32 | 5197 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Column: Change 5-μm packing L##1 to: 5-μm packing L82 |
WITCH HAZEL | Limit of tannins | USP37–NF32 | 5177 | 27-Mar-2015 | 1-Apr-2015 | USP39–NF34 | USP39–NF34 | Line 3 of Chromatographic system: Change 5.0-mm × 15-cm to: 4.6-mm × 15-cm |
WHITE PETROLATUM | IMPURITIES/Organic Impurities/Procedure: Organic Acids | USP37–NF32 | 4254 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Sample solution: Change 20.0 g in 100 mL of neutralized alcohol and water (1:2). to: 20.0 g of White Petrolatum in 100 mL of a 1 in 2 mixture of neutralized alcohol and water. |
WATER-SOLUBLE VITAMINS WITH MINERALS TABLETS | STRENGTH | USP43–NF38 | 5552 | 24-Apr-2020 | 1-May-2020 | NA | NA | In the Calculate statement in Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 1/Analysis: Delete , calcium pantothenate (C18H32CaN2O10), and folic acid (C19… Read More |
WATER-SOLUBLE VITAMINS WITH MINERALS CAPSULES | STRENGTH/Molybdenum, Method 1 | Second Supplement to USP36–NF31 | 6479 | 31-Jan-2014 | 1-Feb-2014 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 2 of Standard solutions: Change 2.0 to: 5.0 |
WATER-SOLUBLE VITAMINS TABLETS | STRENGTH | USP43–NF38 | 5512 | 24-Apr-2020 | 1-May-2020 | NA | NA | In Biotin, Method 3/Solid-phase extraction: Change anion-xchange to: anion-exchange AND In the Calculate statement in Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 1/Analysis: Delete ,… Read More |
WATER FOR INJECTION | ADDITIONAL REQUIREMENTS | USP41–NF36 | 4345 | 26-Oct-2018 | 1-Nov-2018 | USP43–NF38 | Second Supplement to USP41–NF36 | Delete • USP Reference Standards <11> USP 1,4-Benzoquinone RS |
WATER FOR INJECTION | CHEMICAL INFORMATION | USP37–NF32 | 5173 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Add the chemical formula and molecular weight: H2O 18.02 |
WATER FOR HEMODIALYSIS | ADDITIONAL REQUIREMENTS | USP41–NF36 | 4345 | 26-Oct-2018 | 1-Nov-2018 | USP43–NF38 | Second Supplement to USP41–NF36 | Delete • USP Reference Standards <11> USP 1,4-Benzoquinone RS |
WATER FOR HEMODIALYSIS | CHEMICAL INFORMATION | USP37–NF32 | 5173 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Add the chemical formula and molecular weight: H2O 18.02 |
WARFARIN SODIUM TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF Online | Online | 28-Jan-2022 | 1-Feb-2022 | NA | NA | In USP Warfarin Related Compound A RS: Change 3-(o-Hydroxyphenyl)-5-phenyl-2-cyclohexen-1-one. to: 3-(2-Hydroxyphenyl)-5-phenyl-2-cyclohexen-1-one. AND Change 264.33 to: 264.32 |
WARFARIN SODIUM FOR INJECTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF Online | Online | 28-Jan-2022 | 1-Feb-2022 | NA | NA | In USP Warfarin Related Compound A RS: Change 3-(o-Hydroxyphenyl)-5-phenyl-2-cyclohexen-1-one. to: 3-(2-Hydroxyphenyl)-5-phenyl-2-cyclohexen-1-one. AND Change 264.33 to: 264.32 |
VORICONAZOLE | IMPURITIES/Voriconazole Related Compounds C and D | USP42–NF37 | 4601 | 28-Jun-2019 | 1-Jul-2019 | NA | NA | In System suitability solution: Change 0.25 µg/mL of USP Voriconazole RS to: 0.25 µg/mL of USP Voriconazole RS in Mobile phase |
VORICONAZOLE | IDENTIFICATION/A. | USP43–NF38 | 4643 | 25-Sep-2020 | 1-Oct-2020 | NA | NA | Change Infrared Absorption 〈197K〉 to: Spectroscopic Identification Tests 〈197〉, Infrared Spectroscopy: 197K |
VITAMIN E | ASSAY/Alpha Tocopheryl Acid Succinate | USP43–NF38 | 4637 | 24-Apr-2020 | 1-May-2020 | NA | NA | In Sample solution: Change tocoopheryl to: tocopheryl |
VITAMIN E | SPECIFIC TESTS/Acidity | USP36–NF31 | 5579 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 1 of Sample: Change 40 mg to: 1.0 g |
VITAMIN E | IDENTIFICATION/A./Sample solutions | USP37–NF32 | 5163 | 25-Jul-2014 | 1-Aug-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Lines 4 and 7 of Alpha tocopheryl acetate: Change dilute sulfuric acid to: diluted sulfuric acid |
VITAMIN A TABLETS | ASSAY/Procedure 2 | USP43–NF38 | 4635 | 24-Apr-2020 | 1-May-2020 | NA | NA | In the variable definition list in Analysis: Change Sample solution 1 to: Sample solution |
VITAMIN A ORAL LIQUID PREPARATION | ASSAY/Vitamin A | USP39–NF34 | 6374 | 30-Sep-2016 | 1-Oct-2016 | USP41–NF36 | First Supplement to USP40–NF35 | Line 7 of Analysis: Change Result = (rU/rS) × (C/W) × (V/D) × U × (100/L) to: Result = (rU/rS) × (C/W) × D × U… Read More |
VITAMIN A | ADDITIONAL REQUIREMENTS | USP41–NF36 | 4327 | 28-Dec-2018 | 1-Jan-2019 | NA | NA | Change Delete the following ▲•USP Reference Standards <11> USP Retinyl Acetate RS USP Retinyl Palmitate RS ▲(CN 1-May-2018) to: •USP Reference Standards <11> USP Retinyl Acetate RS … Read More |
VINPOCETINE | IMPURITIES/Organic Impurities | USP39–NF34 | 6880 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Footnote a of Table 1: Change Ethyl (12RS,13aSR,13bSR)-13a-ethyl-12-hydroxy-2,3,5,6,12,13,13a,13b-octahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (ethyl vincaminate). to: Ethyl (12S,13aS,13bS… Read More |
VINORELBINE TARTRATE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP39–NF34 | 6370 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 2 of USP Vinorelbine Related Compound A RS: Change 4-O-Deacetylvinorelbine. to: 4-O-Deacetylvinorelbine tartrate. |
VINORELBINE TARTRATE | ASSAY/Procedure | USP35–NF30 | 5027 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Line 1 of Relative standard deviation in System suitability: Change
NLT 2.0% to: NMT 2.0% |
VINORELBINE INJECTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP39–NF34 | 6371 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 2 of USP Vinorelbine Related Compound A RS: Change 4-O-Deacetylvinorelbine. to: 4-O-Deacetylvinorelbine tartrate. |